MAPK8 and perinatal asphyxia: The TAT-JBD peptide may serve as a treatment option for neonatal HIE due to its promising results in reducing neuronal damage and loss of mitochondrial activity through early JNK inhibition, with overall improvements in anatomical outcomes, therefore improving cognitive and behavioral results post-HIE.